基于风险分层与预防性生物制剂使用的术后克罗恩病真实世界手术与内镜复发
这项多中心回顾性分析纳入2009至2020年接受回结肠切除术的1404例成人克罗恩病患者,按高危因素分层并评估术后90天内生物制剂预防对复发的影响。结果显示临床风险因素与手术复发相关但对内镜复发预测有限;无论风险分层,接受预防者内镜复发率均较低。
要点
- ≥2次回结肠切除术(OR 1.71)、活动性吸烟(OR 1.73)、穿透性疾病(OR 1.41)、肛周病变史(OR 1.99)与手术复发相关,与内镜复发无关。
- 高危患者接受预防者手术复发率低于未接受者(10.2% vs 16.7%;P = .02)。
- 高危患者接受预防者内镜复发率低于未接受者(28.1% vs 37.4%;P = .03),低危患者亦然(21.1% vs 38.3%;P = .002)。
核心结论
- 临床风险因素能准确识别有手术复发风险的患者,但预测内镜复发的效用有限。
- 生物制剂预防无论风险分层如何均可能获益,未来研究应评估这一点。
研究设计与样本
- 多中心回顾性分析,纳入2009至2020年接受回结肠切除术的克罗恩病患者,共1404例成人。
- 采用高危特征(活动性吸烟、≥2次既往手术、穿透性疾病和/或肛周病变)与低危特征(不吸烟且年龄>50岁)进行风险分层。
- 通过逻辑回归和时间-事件分析评估风险分层及术后≤90天生物制剂预防对内镜复发(Rutgeert评分≥i2b)和手术复发的影响。
主要发现
- ≥2次回结肠切除术与手术复发相关(OR 1.71;95% CI 1.13-2.57)。
- 活动性吸烟与手术复发相关(OR 1.73;95% CI 1.17-2.53)。
- 穿透性疾病与手术复发相关(OR 1.41;95% CI 1.02-1.94)。
- 单纯肛周病变史与手术复发相关(OR 1.99;95% CI 1.42-2.79)。
- 上述高危因素均与内镜复发无关。
关键数值与推荐
- 高危患者接受预防者手术复发率10.2% vs 未接受者16.7%(P = .02)。
- 高危患者接受预防者内镜复发率28.1% vs 未接受者37.4%(P = .03)。
- 低危患者接受预防者内镜复发率21.1% vs 未接受者38.3%(P = .002)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Preoperative risk stratification may help guide prophylactic biologic utilization for the prevention of postoperative Crohn's disease (CD) recurrence; however, there are limited data exploring and validating proposed clinical risk factors. We aimed to explore the preoperative clinical risk profiles, quantify individual risk factors, and assess the impact of biologic prophylaxis on postoperative recurrence risk in a real-world cohort. METHODS: In this multicenter retrospective analysis, patients with CD who underwent ileocolonic resection (ICR) from 2009 to 2020 were identified. High-risk (active smoking, ≥2 prior surgeries, penetrating disease, and/or perianal disease) and low-risk (nonsmokers and age >50 y) features were used to stratify patients. We assessed the risk of endoscopic (Rutgeert score, ≥i2b) and surgical recurrence by risk strata and biologic prophylaxis (≤90 days postoperatively) with logistic and time-to-event analyses. RESULTS: A total of 1404 adult CD patients who underwent ICR were included. Of the high-risk factors, 2 or more ICRs (odds ratio [OR], 1.71; 95% CI, 1.13-2.57), active smoking (OR, 1.73; 95% CI, 1.17-2.53), penetrating disease (OR, 1.41; 95% CI, 1.02-1.94), and history of perianal disease alone (OR, 1.99; 95% CI, 1.42-2.79) were associated with surgical but not endoscopic recurrence. Surgical recurrence was lower in high-risk patients receiving prophylaxis vs not (10.2% vs 16.7%; P = .02), and endoscopic recurrence was lower in those receiving prophylaxis irrespective of risk strata (high-risk, 28.1% vs 37.4%; P = .03; and low-risk, 21.1% vs 38.3%; P = .002). CONCLUSIONS: Clinical risk factors accurately illustrate patients at risk for surgical recurrence, but have limited utility in predicting endoscopic recurrence. Biologic prophylaxis may be of benefit irrespective of risk stratification and future studies should assess this.
引用
- Shah RS, Bachour S, Joseph A, et al. Real-World Surgical and Endoscopic Recurrence Based on Risk Profiles and Prophylaxis Utilization in Postoperative Crohn's Disease. Clin Gastroenterol Hepatol. 2023. PMID: 37879523. doi:10.1016/j.cgh.2023.10.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。